导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.89% | 2920/4773 |
| 近一周 | -1.93% | 3140/5465 |
| 近一月 | -3.61% | 2683/5421 |
| 近一季 | -7.32% | 2754/5231 |
| 近半年 | -2.83% | 2295/4920 |
| 近一年 | 0.63% | 2658/4394 |
| 近两年 | 45.75% | 1645/2954 |
| 近三年 | 27.22% | 1209/2253 |
| 成立以来 | 12.50% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.82% 3430/4961 |
12.14% 2222/5312 |
- - |
- - |
| 2025 | 19.86% 2175/4813 |
-1.10% 2575/3635 |
2.25% 1712/4076 |
18.57% 2277/4524 |
-0.04% 2322/4813 |
| 2024 | 16.61% 788/3463 |
2.85% 687/2808 |
-1.24% 1002/3014 |
16.48% 1444/3129 |
-1.43% 1699/3463 |
| 2023 | -9.84% 1235/2656 |
4.43% 956/2280 |
-4.11% 1054/2385 |
-3.42% 926/2515 |
-6.77% 1910/2655 |
| 2022 | -20.34% 965/2207 |
-14.71% 986/1919 |
6.93% 574/2016 |
-14.14% 1033/2113 |
1.72% 1165/2208 |
| 2021 | 0.47% 712/1822 |
-2.26% 608/1255 |
6.36% 758/1330 |
-4.76% 733/1466 |
1.48% 909/1822 |
| 2020 | - - |
- - |
- - |
- - |
13.50% 355/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华安沪深300ETF联接C VS. 长安沪深300非周期A(740101) |